Research
Hormonal
GLP-1 receptor agonists provide significant cardiovascular benefits, including reduced risk of major adverse cardiovascular events (MACE) and stroke, in addition to weight loss and glycemic control.
GLP-1 agonists (like Ozempic or Victoza) do more than lower blood sugar and help with weight loss. They have been proven to reduce the risk of heart attacks, strokes, and cardiovascular death in people with Type 2 Diabetes. If you have heart disease or risk factors, these drugs may offer significant protection beyond just sugar control.
GoodSupportsHIGH confidence
High-certainty evidence suggests that SGLT-2i treatment decreases the risk of hospitalization due to HF, and moderate-certainty evidence may support GLP-1RA treatment to reduce fatal and non-fatal strokes.
Why this rating
Supported by moderate-certainty evidence from multiple large RCTs (LEADER, SUSTAIN-6).
Source
New Hypoglycemic Drugs: Combination Drugs and Targets Discovery
Xiayun Ni et al. · Frontiers in Pharmacology · 2022
DOI 10.3389/fphar.2022.877797
narrative_reviewCited 21×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT-2 inhibitors provide cardiovascular and renal protective benefits independent of their glucose-lowering effects, including reduced risk of heart failure hospitalization and worsening renal function.Strong
- Early combination therapy with new hypoglycemic drugs (SGLT-2i, GLP-1RA, or DPP-4i) achieves glycemic control faster and provides longer-lasting benefits compared to traditional stepwise monotherapy in prediabetes and type 2 diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →